Funder
National Natural Science Foundation of China
Subject
Pharmacology,Immunology,Immunology and Allergy
Reference99 articles.
1. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N. Engl. J. Med.,2012
2. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N. Engl. J. Med.,2012
3. Immune checkpoint inhibitors: a patent review (2010–2015);Collin;Expert Opin. Ther. Pat.,2016
4. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study;Plimack;Lancet Oncol.,2017
5. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial;Seiwert;Lancet Oncol.,2016
Cited by
124 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献